January 19, 2024
We ask that Congress finalize the FY 2024 Labor, Health and Human Services, Education, and Related Agencies appropriations bill at or exceeding President Biden’s proposed increase of $36 million, for a total of $67 million to support these critical efforts.
April 30, 2024
The data affected by the proposal are not only used for scientific research intended for dissemination among academic audiences. Rather, these data are routinely used to monitor outcomes, processes of care, access, equity in care delivery, and the effects of policy changes. These data are vital for the development of decision-tools for patients and clinicians.
We appreciate that data for the rapidly emerging field of molecular diagnostic testing is still maturing and that the global costs associated with such testing are significant. However, we feel strongly that molecular diagnostic testing may provide massive clinical and economic benefits in the early detection and management of solid organ allograft rejection. Utilizing molecular testing for detection of allograft injury is an emerging standard of care that can directly aid in clinical decision making and may improve patient and allograft survival. We support the access of transplant patients to these diagnostic technologies and believe that continued Medicare coverage of these tools is critical to further refine their utility and cost effectiveness.
July 18, 2023
Later this week, the Uniform Law Commission will meet to discuss proposed changes to the Uniform Determination of Death Act (UDDA) and hold a first reading of the revised Uniform Declaration of Death Act (rUDDA). On behalf of the American Society of Transplant Surgeons (ASTS) and the undersigned organizations, we write to request consideration not to move forward with the rUDDA.
Stay up to date on our advocacy work, addressing the issues that are important to you as a transplant professional.